stockrowAdicet Bio, Inc.
ACET Healthcare Biotechnology
Adicet Bio, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.0 million.
- EPS
- +63.4%
- Free cash flow
- +24.9%
Quarter to June 2026, against a year earlier
Follow ACET
Alert me
Adicet Bio, Inc. (ACET) EV/Sales
As of 6 November 2026, Adicet Bio, Inc. (ACET) trades at a EV/Sales of −2.2×. Over the past ten years it has ranged from −4.7× (September 2020) to 36.7× (December 2021); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 2.9× | (90.82%) |
| FY2022 | 31.8× | 9.18% |
| FY2021 | 29.1× | 2,067.10% |
| FY2021 | 1.3× | (16.09%) |
| FY2020 | 1.6× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2022 | 13.9× | (52.39%) |
| Dec 2021 | 29.1× | 263.17% |
| Sep 2021 | 8.0× | (46.25%) |
| Jun 2021 | 14.9× | 28.89% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.7× |
| ACET Adicet Bio, Inc. | −2.2× |
| ANVS Annovis Bio, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | 0.4× |
| BYSI BeyondSpring Inc. compare | 15.4× |
| ABVC ABVC BioPharma, Inc. compare | 20.6× |
| EDSA Edesa Biotech, Inc. compare | 28.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)